Nucleophosmin in Its Interaction with Ligands
Abstract
:1. Introduction
2. Role in Cancer
3. Interactions
3.1. Nucleic Acids
3.2. Proteins and Peptides
3.3. Role of NPM1 in Nucleolar Liquid–Liquid Phase Separation
4. Inhibition
4.1. Natural Compounds
4.2. Synthetic Compounds
5. Conclusions
Funding
Conflicts of Interest
References
- Grisendi, S.; Mecucci, C.; Falini, B.; Pandolfi, P.P. Nucleophosmin and cancer. Nat. Rev. Cancer 2006, 6, 493–505. [Google Scholar] [CrossRef] [PubMed]
- Box, J.K.; Paquet, N.; Adams, M.N.; Boucher, D.; Bolderson, E.; O’Byrne, K.J.; Richard, D.J. Nucleophosmin: From structure and function to disease development. BMC. Mol. Biol. 2016, 17, 19. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Heath, E.M.; Chan, S.M.; Minden, M.D.; Murphy, T.; Shlush, L.I.; Schimmer, A.D. Biological and clinical consequences of NPM1 mutations in AML. Leukemia 2017, 31, 798–807. [Google Scholar] [CrossRef] [PubMed]
- Kunchala, P.; Kuravi, S.; Jensen, R.; McGuirk, J.; Balusu, R. When the good go bad: Mutant NPM1 in acute myeloid leukemia. Blood Rev. 2018, 32, 167–183. [Google Scholar] [CrossRef] [PubMed]
- Brunetti, L.; Gundry, M.C.; Goodell, M.A. New insights into the biology of acute myeloid leukemia with mutated NPM1. Int. J. Hematol. 2019, 110, 150–160. [Google Scholar] [CrossRef] [Green Version]
- Brodská, B.; Šašinková, M.; Kuželová, K. Nucleophosmin in leukemia: Consequences of anchor loss. Int. J. Biochem. Cell Biol. 2019, 111, 52–62. [Google Scholar] [CrossRef]
- Maggi, L.B.; Kuchenruether, M.; Dadey, D.Y.A.; Schwope, R.M.; Grisendi, S.; Townsend, R.R.; Pandolfi, P.P.; Weber, J.D. Nucleophosmin Serves as a Rate-Limiting Nuclear Export Chaperone for the Mammalian Ribosome. Mol. Cell. Biol. 2008, 28, 7050–7065. [Google Scholar] [CrossRef] [Green Version]
- Murano, K.; Okuwaki, M.; Hisaoka, M.; Nagata, K. Transcription Regulation of the rRNA Gene by a Multifunctional Nucleolar Protein, B23/Nucleophosmin, through Its Histone Chaperone Activity. Mol. Cell. Biol. 2008, 28, 3114–3126. [Google Scholar] [CrossRef] [Green Version]
- Okuda, M. The role of nucleophosmin in centrosome duplication. Oncogene 2002, 21, 6170–6174. [Google Scholar] [CrossRef] [Green Version]
- Wang, W.; Budhu, A.; Forgues, M.; Wang, X.W. Temporal and spatial control of nucleophosmin by the Ran–Crm1 complex in centrosome duplication. Nat. Cell Biol. 2005, 7, 823–830. [Google Scholar] [CrossRef]
- Ziv, O.; Zeisel, A.; Mirlas-Neisberg, N.; Swain, U.; Nevo, R.; Ben-Chetrit, N.; Martelli, M.P.; Rossi, R.; Schiesser, S.; Canman, C.E.; et al. Identification of novel DNA-damage tolerance genes reveals regulation of translesion DNA synthesis by nucleophosmin. Nat. Commun. 2014, 5, 5437. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Scott, D.D.; Oeffinger, M. Nucleolin and nucleophosmin: Nucleolar proteins with multiple functions in DNA repair. Biochem. Cell Biol. 2016, 94, 419–432. [Google Scholar] [CrossRef]
- Szebeni, A.; Olson, M.O.J. Nucleolar protein B23 has molecular chaperone activities. Protein Sci. 1999, 8, 905–912. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Okuwaki, M.; Matsumoto, K.; Tsujimoto, M.; Nagata, K. Function of nucleophosmin/B23, a nucleolar acidic protein, as a histone chaperone. FEBS Lett. 2001, 506, 272–276. [Google Scholar] [CrossRef] [Green Version]
- Colombo, E.; Alcalay, M.; Pelicci, P.G. Nucleophosmin and its complex network: A possible therapeutic target in hematological diseases. Oncogene 2011, 30, 2595–2609. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Feric, M.; Vaidya, N.; Harmon, T.S.; Mitrea, D.M.; Zhu, L.; Richardson, T.M.; Kriwacki, R.W.; Pappu, R.V.; Brangwynne, C.P. Coexisting Liquid Phases Underlie Nucleolar Subcompartments. Cell 2016, 165, 1686–1697. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mitrea, D.M.; Cika, J.A.; Stanley, C.B.; Nourse, A.; Onuchic, P.L.; Banerjee, P.R.; Phillips, A.H.; Park, C.-G.; Deniz, A.A.; Kriwacki, R.W. Self-interaction of NPM1 modulates multiple mechanisms of liquid–liquid phase separation. Nat. Commun. 2018, 9, 842. [Google Scholar] [CrossRef]
- Wang, D.; Umewaka, H.; Olson, M.O. Expression and Subcellular Locations of Two Forms of Nucleolar Protein B23 in Rat Tissues and Cells. Cell. Mol. Biol. Res. 1993, 39, 33–42. [Google Scholar]
- Zajac, M.; Dolnik, A.; Stasiak, G.; Zaleska, J.; Kielbus, M.; Czapinski, J.; Schunn, M.; Correa, S.C.; Glodkowska-Mrowka, E.; Sundaram, R.C.; et al. Analysis of NPM1 splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia. Oncotarget 2017, 8, 95163–95175. [Google Scholar] [CrossRef] [Green Version]
- Lim, M.J.; Wang, X.W. Nucleophosmin and human cancer. Cancer Detect. Prev. 2006, 30, 481–490. [Google Scholar] [CrossRef] [Green Version]
- Sakashita, G.; Kiyoi, H.; Naoe, T.; Urano, T. Analysis of the oligomeric states of nucleophosmin using size exclusion chromatography. Sci. Rep. 2018, 8, 4008. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Okuwaki, M.; Tsujimoto, M.; Nagata, K. The RNA Binding Activity of a Ribosome Biogenesis Factor, Nucleophosmin/B23, Is Modulated by Phosphorylation with a Cell Cycle-dependent Kinase and by Association with Its Subtype. Mol. Biol. Cell 2002, 13, 2016–2030. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dalenc, F.; Drouet, J.; Ader, I.; Delmas, C.; Rochaix, P.; Favre, G.; Cohen-Jonathan, E.; Toulas, C. Increased expression of a COOH-truncated nucleophosmin resulting from alternative splicing is associated with cellular resistance to ionizing radiation in HeLa cells. Int. J. Cancer 2002, 100, 662–668. [Google Scholar] [CrossRef] [PubMed]
- Hingorani, K.; Szebeni, A.; Olson, M.O.J. Mapping the Functional Domains of Nucleolar Protein B23. J. Biol. Chem. 2000, 275, 24451–24457. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Frehlick, L.J.; Eirín-López, J.M.; Ausió, J. New insights into the nucleophosmin/nucleoplasmin family of nuclear chaperones. Bioessays 2007, 29, 49–59. [Google Scholar] [CrossRef]
- Mitrea, D.M.; Grace, C.R.; Buljan, M.; Yun, M.-K.; Pytel, N.J.; Satumba, J.; Nourse, A.; Park, C.-G.; Madan Babu, M.; White, S.W.; et al. Structural polymorphism in the N-terminal oligomerization domain of NPM1. Proc. Natl. Acad. Sci. USA 2014, 111, 4466–4471. [Google Scholar] [CrossRef] [Green Version]
- Lee, H.H.; Kim, H.S.; Kang, J.Y.; Lee, B.I.; Ha, J.Y.; Yoon, H.J.; Lim, S.O.; Jung, G.; Suh, S.W. Crystal structure of human nucleophosmin-core reveals plasticity of the pentamer-pentamer interface. Proteins 2007, 69, 672–678. [Google Scholar] [CrossRef]
- Namboodiri, V.M.H.; Akey, I.V.; Schmidt-Zachmann, M.S.; Head, J.F.; Akey, C.W. The Structure and Function of Xenopus NO38-Core, a Histone Chaperone in the Nucleolus. Structure 2004, 12, 2149–2160. [Google Scholar] [CrossRef] [Green Version]
- Marasco, D.; Ruggiero, A.; Vascotto, C.; Poletto, M.; Scognamiglio, P.L.; Tell, G.; Vitagliano, L. Role of mutual interactions in the chemical and thermal stability of nucleophosmin NPM1 domains. Biochem. Biophys. Res. Commun. 2013, 430, 523–528. [Google Scholar] [CrossRef]
- Banerjee, P.R.; Mitrea, D.M.; Kriwacki, R.W.; Deniz, A.A. Asymmetric Modulation of Protein Order-Disorder Transitions by Phosphorylation and Partner Binding. Angew. Chem. Int. Ed. 2016, 55, 1675–1679. [Google Scholar] [CrossRef] [Green Version]
- Yu, Y.; Maggi, L.B.; Brady, S.N.; Apicelli, A.J.; Dai, M.-S.; Lu, H.; Weber, J.D. Nucleophosmin Is Essential for Ribosomal Protein L5 Nuclear Export. Mol. Cell Biol. 2006, 26, 3798–3809. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Eirín-López, J.M.; Frehlick, L.J.; Ausió, J. Long-Term Evolution and Functional Diversification in the Members of the Nucleophosmin/Nucleoplasmin Family of Nuclear Chaperones. Genetics 2006, 173, 1835–1850. [Google Scholar] [CrossRef] [Green Version]
- Mitrea, D.M.; Cika, J.A.; Guy, C.S.; Ban, D.; Banerjee, P.R.; Stanley, C.B.; Nourse, A.; Deniz, A.A.; Kriwacki, R.W. Nucleophosmin integrates within the nucleolus via multi-modal interactions with proteins displaying R-rich linear motifs and rRNA. eLife 2016, 5, e13571. [Google Scholar] [CrossRef] [PubMed]
- Gadad, S.S.; Senapati, P.; Syed, S.H.; Rajan, R.E.; Shandilya, J.; Swaminathan, V.; Chatterjee, S.; Colombo, E.; Dimitrov, S.; Pelicci, P.G.; et al. The Multifunctional Protein Nucleophosmin (NPM1) Is a Human Linker Histone H1 Chaperone. Biochemistry 2011, 50, 2780–2789. [Google Scholar] [CrossRef] [PubMed]
- Swaminathan, V.; Kishore, A.H.; Febitha, K.K.; Kundu, T.K. Human Histone Chaperone Nucleophosmin Enhances Acetylation-Dependent Chromatin Transcription. Mol. Cell Biol. 2005, 25, 7534–7545. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Federici, L.; Arcovito, A.; Scaglione, G.L.; Scaloni, F.; Lo Sterzo, C.; Di Matteo, A.; Falini, B.; Giardina, B.; Brunori, M. Nucleophosmin C-terminal Leukemia-associated Domain Interacts with G-rich Quadruplex Forming DNA. J. Biol. Chem. 2010, 285, 37138–37149. [Google Scholar] [CrossRef] [Green Version]
- Arcovito, A.; Chiarella, S.; Della Longa, S.; Di Matteo, A.; Lo Sterzo, C.; Scaglione, G.L.; Federici, L. Synergic Role of Nucleophosmin Three-helix Bundle and a Flanking Unstructured Tail in the Interaction with G-quadruplex DNA. J. Biol. Chem. 2014, 289, 21230–21241. [Google Scholar] [CrossRef] [Green Version]
- Grummitt, C.G.; Townsley, F.M.; Johnson, C.M.; Warren, A.J.; Bycroft, M. Structural Consequences of Nucleophosmin Mutations in Acute Myeloid Leukemia. J. Biol. Chem. 2008, 283, 23326–23332. [Google Scholar] [CrossRef] [Green Version]
- Federici, L.; Falini, B. Nucleophosmin mutations in acute myeloid leukemia: A tale of protein unfolding and mislocalization: Unfolding and Mislocalization of NPM1 Mutants in AML. Protein Sci. 2013, 22, 545–556. [Google Scholar] [CrossRef] [Green Version]
- Nishimura, Y.; Ohkubo, T.; Furuichi, Y.; Umekawa, H. Tryptophans 286 and 288 in the C-terminal Region of Protein B23.1 are Important for Its Nucleolar Localization. Biosci. Biotechnol. Biochem. 2002, 66, 2239–2242. [Google Scholar] [CrossRef] [Green Version]
- Falini, B.; Bolli, N.; Shan, J.; Martelli, M.P.; Liso, A.; Pucciarini, A.; Bigerna, B.; Pasqualucci, L.; Mannucci, R.; Rosati, R.; et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood 2006, 107, 4514–4523. [Google Scholar] [CrossRef]
- Chiarella, S.; De Cola, A.; Scaglione, G.L.; Carletti, E.; Graziano, V.; Barcaroli, D.; Lo Sterzo, C.; Di Matteo, A.; Di Ilio, C.; Falini, B.; et al. Nucleophosmin mutations alter its nucleolar localization by impairing G-quadruplex binding at ribosomal DNA. Nucleic Acids Res. 2013, 41, 3228–3239. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Léotoing, L.; Meunier, L.; Manin, M.; Mauduit, C.; Decaussin, M.; Verrijdt, G.; Claessens, F.; Benahmed, M.; Veyssière, G.; Morel, L.; et al. Influence of nucleophosmin/B23 on DNA binding and transcriptional activity of the androgen receptor in prostate cancer cell. Oncogene 2008, 27, 2858–2867. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Londero, A.P.; Orsaria, M.; Tell, G.; Marzinotto, S.; Capodicasa, V.; Poletto, M.; Vascotto, C.; Sacco, C.; Mariuzzi, L. Expression and Prognostic Significance of APE1/Ref-1 and NPM1 Proteins in High-Grade Ovarian Serous Cancer. Am. J. Clin. Pathol. 2014, 141, 404–414. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sekhar, K.R.; Benamar, M.; Venkateswaran, A.; Sasi, S.; Penthala, N.R.; Crooks, P.A.; Hann, S.R.; Geng, L.; Balusu, R.; Abbas, T.; et al. Targeting Nucleophosmin 1 Represents a Rational Strategy for Radiation Sensitization. Int. J. Radiat. Oncol. Biol. Phys. 2014, 89, 1106–1114. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yun, J.-P.; Miao, J.; Chen, G.G.; Tian, Q.-H.; Zhang, C.-Q.; Xiang, J.; Fu, J.; Lai, P.B.S. Increased expression of nucleophosmin/B23 in hepatocellular carcinoma and correlation with clinicopathological parameters. Br. J. Cancer 2007, 96, 477–484. [Google Scholar] [CrossRef] [Green Version]
- Pianta, A.; Puppin, C.; Franzoni, A.; Fabbro, D.; Di Loreto, C.; Bulotta, S.; Deganuto, M.; Paron, I.; Tell, G.; Puxeddu, E.; et al. Nucleophosmin is overexpressed in thyroid tumors. Biochem. Biophys. Res. Commun. 2010, 397, 499–504. [Google Scholar] [CrossRef]
- Liu, Y.; Zhang, F.; Zhang, X.; Qi, L.; Yang, L.; Guo, H.; Zhang, N. Expression of Nucleophosmin/NPM1 correlates with migration and invasiveness of colon cancer cells. J. Biomed. Sci. 2012, 19, 53. [Google Scholar] [CrossRef] [Green Version]
- Zhu, Y.; Shi, M.; Chen, H.; Gu, J.; Zhang, J.; Shen, B.; Deng, X.; Xie, J.; Zhan, X.; Peng, C. NPM1 activates metabolic changes by inhibiting FBP1 while promoting the tumorigenicity of pancreatic cancer cells. Oncotarget 2015, 6, 21443–21451. [Google Scholar] [CrossRef] [Green Version]
- Chen, J.; Sun, J.; Yang, L.; Yan, Y.; Shi, W.; Shi, J.; Huang, Q.; Chen, J.; Lan, Q. Upregulation of B23 promotes tumor cell proliferation and predicts poor prognosis in glioma. Biochem. Biophys. Res. Commun. 2015, 466, 124–130. [Google Scholar] [CrossRef]
- Holmberg Olausson, K.; Elsir, T.; Moazemi Goudarzi, K.; Nistér, M.; Lindström, M.S. NPM1 histone chaperone is upregulated in glioblastoma to promote cell survival and maintain nucleolar shape. Sci. Rep. 2015, 5, 16495. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kuo, Y.-H.; Chen, Y.-T.; Tsai, H.-P.; Chai, C.-Y.; Kwan, A.-L. Nucleophosmin overexpression is associated with poor survival in astrocytoma. APMIS 2015, 123, 515–522. [Google Scholar] [CrossRef] [PubMed]
- Chen, S.; He, H.; Wang, Y.; Liu, L.; Liu, Y.; You, H.; Dong, Y.; Lyu, J. Poor prognosis of nucleophosmin overexpression in solid tumors: A meta-analysis. Bmc Cancer 2018, 18, 838. [Google Scholar] [CrossRef]
- Lindström, M.S. NPM1/B23: A Multifunctional Chaperone in Ribosome Biogenesis and Chromatin Remodeling. Biochem. Res. Int. 2011, 2011, 1–16. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Poletto, M.; Lirussi, L.; Wilson, D.M.; Tell, G. Nucleophosmin modulates stability, activity, and nucleolar accumulation of base excision repair proteins. Mol. Biol. Cell 2014, 25, 1641–1652. [Google Scholar] [CrossRef] [PubMed]
- Werner, M.T.; Zhao, C.; Zhang, Q.; Wasik, M.A. Nucleophosmin-anaplastic lymphoma kinase: The ultimate oncogene and therapeutic target. Blood 2017, 129, 823–831. [Google Scholar] [CrossRef] [Green Version]
- Adams, J.; Nassiri, M. Acute Promyelocytic Leukemia: A Review and Discussion of Variant Translocations. Arch. Pathol. Lab. Med. 2015, 139, 1308–1313. [Google Scholar] [CrossRef] [Green Version]
- Yoneda-Kato, N.; Fukuhara, S.; Kato, J. Apoptosis induced by the myelodysplastic syndrome-associated NPM-MLF1 chimeric protein. Oncogene 1999, 18, 3716–3724. [Google Scholar] [CrossRef] [Green Version]
- Velusamy, T.; Kiel, M.J.; Sahasrabuddhe, A.A.; Rolland, D.; Dixon, C.A.; Bailey, N.G.; Betz, B.L.; Brown, N.A.; Hristov, A.C.; Wilcox, R.A.; et al. A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders. Blood 2014, 124, 3768–3771. [Google Scholar] [CrossRef] [Green Version]
- Akahane, K.; Sanda, T.; Mansour, M.R.; Radimerski, T.; DeAngelo, D.J.; Weinstock, D.M.; Look, A.T. HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia. Leukemia 2016, 30, 219–228. [Google Scholar] [CrossRef] [Green Version]
- Kjeldsen, E. A novel insertion ins(18;5)(q21.1;q31.2q35.1) in acute myeloid leukemia associated with microdeletions at 5q31.2, 5q35.1q35.2 and 18q12.3q21.1 detected by oligobased array comparative genomic hybridization. Mol. Cytogenet. 2014, 7, 63. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Berger, R.; Busson, M.; Baranger, L.; Hélias, C.; Lessard, M.; Dastugue, N.; Speleman, F. Loss of the NPM1 gene in myeloid disorders with chromosome 5 rearrangements. Leukemia 2006, 20, 319–321. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ebert, B.L. Genetic deletions in AML and MDS. Best Pract. Res. Clin. Haematol. 2010, 23, 457–461. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- La Starza, R.; Barba, G.; Demeyer, S.; Pierini, V.; Di Giacomo, D.; Gianfelici, V.; Schwab, C.; Matteucci, C.; Vicente, C.; Cools, J.; et al. Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia. Haematologica 2016, 101, 951–958. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Falini, B.; Mecucci, C.; Tiacci, E.; Alcalay, M.; Rosati, R.; Pasqualucci, L.; La Starza, R.; Diverio, D.; Colombo, E.; Santucci, A.; et al. Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype. N. Engl. J. Med. 2005, 352, 254–266. [Google Scholar] [CrossRef] [PubMed]
- Falini, B.; Gionfriddo, I.; Cecchetti, F.; Ballanti, S.; Pettirossi, V.; Martelli, M.P. Acute myeloid leukemia with mutated nucleophosmin (NPM1): Any hope for a targeted therapy? Blood Rev. 2011, 25, 247–254. [Google Scholar] [CrossRef] [PubMed]
- Grisendi, S.; Bernardi, R.; Rossi, M.; Cheng, K.; Khandker, L.; Manova, K.; Pandolfi, P.P. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005, 437, 147–153. [Google Scholar] [CrossRef]
- Colombo, E.; Martinelli, P.; Zamponi, R.; Shing, D.C.; Bonetti, P.; Luzi, L.; Volorio, S.; Bernard, L.; Pruneri, G.; Alcalay, M.; et al. Delocalization and Destabilization of the Arf Tumor Suppressor by the Leukemia-Associated NPM Mutant. Cancer Res. 2006, 66, 3044–3050. [Google Scholar] [CrossRef] [Green Version]
- Vascotto, C.; Lirussi, L.; Poletto, M.; Tiribelli, M.; Damiani, D.; Fabbro, D.; Damante, G.; Demple, B.; Colombo, E.; Tell, G. Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: Impact on tumor biology. Oncogene 2014, 33, 2876–2887. [Google Scholar] [CrossRef]
- Bonetti, P.; Davoli, T.; Sironi, C.; Amati, B.; Pelicci, P.G.; Colombo, E. Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7γ. J. Cell Biol. 2008, 182, 19–26. [Google Scholar] [CrossRef] [Green Version]
- Gu, X.; Ebrahem, Q.; Mahfouz, R.Z.; Hasipek, M.; Enane, F.; Radivoyevitch, T.; Rapin, N.; Przychodzen, B.; Hu, Z.; Balusu, R.; et al. Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. J. Clin. Investig. 2018, 128, 4260–4279. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Leong, S.M.; Tan, B.X.; Bte Ahmad, B.; Yan, T.; Chee, L.Y.; Ang, S.T.; Tay, K.G.; Koh, L.P.; Yeoh, A.E.J.; Koay, E.S.-C.; et al. Mutant nucleophosmin deregulates cell death and myeloid differentiation through excessive caspase-6 and -8 inhibition. Blood 2010, 116, 3286–3296. [Google Scholar] [CrossRef] [PubMed]
- Noguera, N.I.; Song, M.S.; Divona, M.; Catalano, G.; Calvo, K.L.; García, F.; Ottone, T.; Florenzano, F.; Faraoni, I.; Battistini, L.; et al. Nucleophosmin/B26 regulates PTEN through interaction with HAUSP in acute myeloid leukemia. Leukemia 2013, 27, 1037–1043. [Google Scholar] [CrossRef] [PubMed]
- Falini, B.; Nicoletti, I.; Bolli, N.; Martelli, M.P.; Liso, A.; Gorello, P.; Mandelli, F.; Mecucci, C.; Martelli, M.F. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica 2007, 92, 519–532. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Arber, D.A.; Orazi, A.; Hasserjian, R.; Thiele, J.; Borowitz, M.J.; Le Beau, M.M.; Bloomfield, C.D.; Cazzola, M.; Vardiman, J.W. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016, 127, 2391–2405. [Google Scholar] [CrossRef] [PubMed]
- Kawaguchi-Ihara, N.; Itoh, M.; Murohashi, I.; Tohda, S. Establishment of a quenching probe method for detection of NPM1 mutations in acute myeloid leukemia cells. Oncol. Lett. 2016, 11, 2429–2432. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Alpermann, T.; Schnittger, S.; Eder, C.; Dicker, F.; Meggendorfer, M.; Kern, W.; Schmid, C.; Aul, C.; Staib, P.; Wendtner, C.-M.; et al. Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia. Haematologica 2016, 101, e55–e58. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Papaemmanuil, E.; Gerstung, M.; Bullinger, L.; Gaidzik, V.I.; Paschka, P.; Roberts, N.D.; Potter, N.E.; Heuser, M.; Thol, F.; Bolli, N.; et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N. Engl. J. Med. 2016, 374, 2209–2221. [Google Scholar] [CrossRef]
- Borrow, J.; Dyer, S.A.; Akiki, S.; Griffiths, M.J. Molecular roulette: Nucleophosmin mutations in AML are orchestrated through N-nucleotide addition by TdT. Blood 2019, 134, 2291–2303. [Google Scholar] [CrossRef]
- Borrow, J.; Dyer, S.A.; Akiki, S.; Griffiths, M.J. Terminal deoxynucleotidyl transferase promotes acute myeloid leukemia by priming FLT3-ITD replication slippage. Blood 2019, 134, 2281–2290. [Google Scholar] [CrossRef]
- Metzeler, K.H.; Herold, T.; Rothenberg-Thurley, M.; Amler, S.; Sauerland, M.C.; Görlich, D.; Schneider, S.; Konstandin, N.P.; Dufour, A.; Bräundl, K.; et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood 2016, 128, 686–698. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shlush, L.I.; Zandi, S.; Mitchell, A.; Chen, W.C.; Brandwein, J.M.; Gupta, V.; Kennedy, J.A.; Schimmer, A.D.; Schuh, A.C.; Yee, K.W.; et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014, 506, 328–333. [Google Scholar] [CrossRef] [PubMed]
- Patel, J.L.; Schumacher, J.A.; Frizzell, K.; Sorrells, S.; Shen, W.; Clayton, A.; Jattani, R.; Kelley, T.W. Coexisting and cooperating mutations in NPM1 -mutated acute myeloid leukemia. Leuk. Res. 2017, 56, 7–12. [Google Scholar] [CrossRef] [PubMed]
- Martelli, M.P.; Sportoletti, P.; Tiacci, E.; Martelli, M.F.; Falini, B. Mutational landscape of AML with normal cytogenetics: Biological and clinical implications. Blood Rev. 2013, 27, 13–22. [Google Scholar] [CrossRef] [PubMed]
- The Cancer Genome Atlas Research Network Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. N. Engl. J. Med. 2013, 368, 2059–2074. [CrossRef] [Green Version]
- Nachmani, D.; Bothmer, A.H.; Grisendi, S.; Mele, A.; Bothmer, D.; Lee, J.D.; Monteleone, E.; Cheng, K.; Zhang, Y.; Bester, A.C.; et al. Germline NPM1 mutations lead to altered rRNA 2′-O-methylation and cause dyskeratosis congenita. Nat. Genet. 2019, 51, 1518–1529. [Google Scholar] [CrossRef] [PubMed]
- Dumbar, T.S.; Gentry, G.A.; Olson, M.O.J. Interaction of nucleolar phosphoprotein B23 with nucleic acids. Biochemistry 1989, 28, 9495–9501. [Google Scholar] [CrossRef]
- Wang, D.; Baumann, A.; Szebeni, A.; Olson, M.O. The nucleic acid binding activity of nucleolar protein B23.1 resides in its carboxyl-terminal end. J. Biol. Chem. 1994, 269, 30994–30998. [Google Scholar]
- Herrera, J.E.; Savkur, R.; Olson, M.O.J. The ribonuclease activity of nucleolar protein B23. Nucl. Acids Res. 1995, 23, 3974–3980. [Google Scholar] [CrossRef]
- Scaloni, F.; Gianni, S.; Federici, L.; Falini, B.; Brunori, M. Folding mechanism of the C-terminal domain of nucleophosmin: Residual structure in the denatured state and its pathophysiological significance. FASEB J. 2009, 23, 2360–2365. [Google Scholar] [CrossRef]
- Scaloni, F.; Federici, L.; Brunori, M.; Gianni, S. Deciphering the folding transition state structure and denatured state properties of Nucleophosmin C-terminal domain. Proc. Natl. Acad. Sci. USA 2010, 107, 5447–5452. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xu, Y.; Fang, F.; Dhar, S.K.; St. Clair, W.H.; Kasarskis, E.J.; St. Clair, D.K. The Role of a Single-stranded Nucleotide Loop in Transcriptional Regulation of the Human sod2 Gene. J. Biol. Chem. 2007, 282, 15981–15994. [Google Scholar] [CrossRef] [Green Version]
- Bañuelos, S.; Lectez, B.; Taneva, S.G.; Ormaza, G.; Alonso-Mariño, M.; Calle, X.; Urbaneja, M.A. Recognition of intermolecular G-quadruplexes by full length nucleophosmin. Effect of a leukaemia-associated mutation. FEBS Lett. 2013, 587, 2254–2259. [Google Scholar] [CrossRef] [Green Version]
- Scognamiglio, P.L.; Di Natale, C.; Leone, M.; Poletto, M.; Vitagliano, L.; Tell, G.; Marasco, D. G-quadruplex DNA recognition by nucleophosmin: New insights from protein dissection. Biochim. Biophys. Acta Gen. Subj. 2014, 1840, 2050–2059. [Google Scholar] [CrossRef] [PubMed]
- Gallo, A.; Lo Sterzo, C.; Mori, M.; Di Matteo, A.; Bertini, I.; Banci, L.; Brunori, M.; Federici, L. Structure of Nucleophosmin DNA-binding Domain and Analysis of Its Complex with a G-quadruplex Sequence from the c- MYC Promoter. J. Biol. Chem. 2012, 287, 26539–26548. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shandilya, J.; Swaminathan, V.; Gadad, S.S.; Choudhari, R.; Kodaganur, G.S.; Kundu, T.K. Acetylated NPM1 Localizes in the Nucleoplasm and Regulates Transcriptional Activation of Genes Implicated in Oral Cancer Manifestation. Mol. Cell Biol. 2009, 29, 5115–5127. [Google Scholar] [CrossRef] [Green Version]
- Drygin, D.; Siddiqui-Jain, A.; O’Brien, S.; Schwaebe, M.; Lin, A.; Bliesath, J.; Ho, C.B.; Proffitt, C.; Trent, K.; Whitten, J.P.; et al. Anticancer Activity of CX-3543: A Direct Inhibitor of rRNA Biogenesis. Cancer Res. 2009, 69, 7653–7661. [Google Scholar] [CrossRef] [Green Version]
- Hisaoka, M.; Nagata, K.; Okuwaki, M. Intrinsically disordered regions of nucleophosmin/B23 regulate its RNA binding activity through their inter- and intra-molecular association. Nucleic Acids Res. 2014, 42, 1180–1195. [Google Scholar] [CrossRef] [Green Version]
- Guo, X.; Bulyk, M.L.; Hartemink, A.J. Intrinsic Disorder Within and Flanking the DNA-binding Domains of Human Transcription Factors. In Proceedings of the Biocomputing 2012; WORLD SCIENTIFIC: Kohala Coast, HI, USA, 2011; pp. 104–115. [Google Scholar]
- Lindström, M.S.; Zhang, Y. Ribosomal Protein S9 Is a Novel B23/NPM-binding Protein Required for Normal Cell Proliferation. J. Biol. Chem. 2008, 283, 15568–15576. [Google Scholar] [CrossRef] [Green Version]
- Wanzel, M.; Russ, A.C.; Kleine-Kohlbrecher, D.; Colombo, E.; Pelicci, P.-G.; Eilers, M. A ribosomal protein L23-nucleophosmin circuit coordinates Miz1 function with cell growth. Nat. Cell Biol. 2008, 10, 1051–1061. [Google Scholar] [CrossRef]
- Itahana, K.; Bhat, K.P.; Jin, A.; Itahana, Y.; Hawke, D.; Kobayashi, R.; Zhang, Y. Tumor Suppressor ARF Degrades B23, a Nucleolar Protein Involved in Ribosome Biogenesis and Cell Proliferation. Mol. Cell 2003, 12, 1151–1164. [Google Scholar] [CrossRef]
- Fankhauser, C.; Izaurralde, E.; Adachi, Y.; Wingfield, P.; Laemmli, U.K. Specific complex of human immunodeficiency virus type 1 rev and nucleolar B23 proteins: Dissociation by the Rev response element. Mol. Cell. Biol. 1991, 11, 2567–2575. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, S.J.; Shim, H.Y.; Hsieh, A.; Min, J.Y.; Jung, G.H. Hepatitis B virus core interacts with the host cell nucleolar protein, nucleophosmin 1. J. Microbiol. 2009, 47, 746–752. [Google Scholar] [CrossRef] [PubMed]
- Okuwaki, M.; Iwamatsu, A.; Tsujimoto, M.; Nagata, K. Identification of nucleophosmin/B23, an acidic nucleolar protein, as a stimulatory factor for in vitro replication of adenovirus DNA complexed with viral basic core proteins. J. Mol. Biol. 2001, 311, 41–55. [Google Scholar] [CrossRef]
- Lobaina, Y.; Perera, Y. Implication of B23/NPM1 in Viral Infections, Potential Uses of B23/NPM1 Inhibitors as Antiviral Therapy. Infect. Disord. Drug Targets 2019, 19, 2–16. [Google Scholar] [CrossRef] [PubMed]
- Adachi, Y.; Copeland, T.D.; Hatanaka, M.; Oroszlan, S. Nucleolar Targeting Signal of Rex Protein of Human T-cell Leukemia Virus Type I Specifically Binds to Nucleolar Shuttle Protein B-23. J. Biol. Chem. 1993, 268, 13930–13934. [Google Scholar]
- Tsuda, Y.; Mori, Y.; Abe, T.; Yamashita, T.; Okamoto, T.; Ichimura, T.; Moriishi, K.; Matsuura, Y. Nucleolar Protein B23 Interacts with Japanese Encephalitis Virus Core Protein and Participates in Viral Replication. Microbiol. Immunol. 2006, 50, 225–234. [Google Scholar] [CrossRef]
- Nouri, K.; Moll, J.M.; Milroy, L.-G.; Hain, A.; Dvorsky, R.; Amin, E.; Lenders, M.; Nagel-Steger, L.; Howe, S.; Smits, S.H.J.; et al. Biophysical Characterization of Nucleophosmin Interactions with Human Immunodeficiency Virus Rev and Herpes Simplex Virus US11. PLoS ONE 2015, 10, e0143634. [Google Scholar] [CrossRef] [Green Version]
- Bertwistle, D.; Sugimoto, M.; Sherr, C.J. Physical and Functional Interactions of the Arf Tumor Suppressor Protein with Nucleophosmin/B23. Mol. Cell Biol. 2004, 24, 985–996. [Google Scholar] [CrossRef] [Green Version]
- Brady, S.N.; Yu, Y.; Maggi, L.B.; Weber, J.D. ARF Impedes NPM/B23 Shuttling in an Mdm2-Sensitive Tumor Suppressor Pathway. Mol. Cell Biol. 2004, 24, 9327–9338. [Google Scholar] [CrossRef] [Green Version]
- DiGiammarino, E.L.; Filippov, I.; Weber, J.D.; Bothner, B.; Kriwacki, R.W. Solution Structure of the p53 Regulatory Domain of the p19Arf Tumor Suppressor Protein. Biochemistry 2001, 40, 2379–2386. [Google Scholar] [CrossRef] [PubMed]
- Luchinat, E.; Chiarella, S.; Franceschini, M.; Di Matteo, A.; Brunori, M.; Banci, L.; Federici, L. Identification of a novel nucleophosmin-interaction motif in the tumor suppressor p14arf. FEBS J. 2018, 285, 832–847. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Scott, M.S.; Troshin, P.V.; Barton, G.J. NoD: A Nucleolar localization sequence detector for eukaryotic and viral proteins. BMC Bioinform. 2011, 12, 317. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Di Matteo, A.; Franceschini, M.; Paiardini, A.; Grottesi, A.; Chiarella, S.; Rocchio, S.; Di Natale, C.; Marasco, D.; Vitagliano, L.; Travaglini-Allocatelli, C.; et al. Structural investigation of nucleophosmin interaction with the tumor suppressor Fbw7γ. Oncogenesis 2017, 6, e379. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mitrea, D.M.; Kriwacki, R.W. On the relationship status for Arf and NPM1 – it’s complicated. FEBS J. 2018, 285, 828–831. [Google Scholar] [CrossRef]
- Fontana, R.; Ranieri, M.; La Mantia, G.; Vivo, M. Dual Role of the Alternative Reading Frame ARF Protein in Cancer. Biomolecules 2019, 9, 87. [Google Scholar] [CrossRef] [Green Version]
- Di Matteo, A.; Franceschini, M.; Chiarella, S.; Rocchio, S.; Travaglini-Allocatelli, C.; Federici, L. Molecules that target nucleophosmin for cancer treatment: An update. Oncotarget 2016, 7, 44821–44840. [Google Scholar] [CrossRef] [Green Version]
- MacGowan, S.A.; Madeira, F.; Britto-Borges, T.; Warowny, M.; Drozdetskiy, A.; Procter, J.B.; Barton, G.J. The Dundee Resource for Sequence Analysis and Structure Prediction. Protein Sci. 2020, 29, 277–297. [Google Scholar] [CrossRef] [Green Version]
- Weeks, S.E.; Metge, B.J.; Samant, R.S. The nucleolus: A central response hub for the stressors that drive cancer progression. Cell. Mol. Life Sci. 2019, 76, 4511–4524. [Google Scholar] [CrossRef] [Green Version]
- Holmberg Olausson, K.; Nistér, M.; Lindström, M.S. Loss of Nucleolar Histone Chaperone NPM1 Triggers Rearrangement of Heterochromatin and Synergizes with a Deficiency in DNA Methyltransferase DNMT3A to Drive Ribosomal DNA Transcription. J. Biol. Chem. 2014, 289, 34601–34619. [Google Scholar] [CrossRef] [Green Version]
- Ferrolino, M.C.; Mitrea, D.M.; Michael, J.R.; Kriwacki, R.W. Compositional adaptability in NPM1-SURF6 scaffolding networks enabled by dynamic switching of phase separation mechanisms. Nat. Commun. 2018, 9, 5064. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Moraleva, A.; Magoulas, C.; Polzikov, M.; Hacot, S.; Mertani, H.C.; Diaz, J.-J.; Zatsepina, O. Involvement of the specific nucleolar protein SURF6 in regulation of proliferation and ribosome biogenesis in mouse NIH/3T3 fibroblasts. Cell Cycle 2017, 16, 1979–1991. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gibbs, E.; Perrone, B.; Hassan, A.; Kümmerle, R.; Kriwacki, R. NPM1 exhibits structural and dynamic heterogeneity upon phase separation with the p14ARF tumor suppressor. J. Magn. Reson. 2020, 310, 106646. [Google Scholar] [CrossRef] [PubMed]
- Chen, Y.; Hu, J. Nucleophosmin1 (NPM1) abnormality in hematologic malignancies, and therapeutic targeting of mutant NPM1 in acute myeloid leukemia. Ther. Adv. Hematol. 2020, 11, 2040620719899818. [Google Scholar] [CrossRef]
- Fenical, W.; Jensen, P.R.; Cheng, X.C. Avrainvillamide, a Cytotoxic Marine Natural Product, and Derivatives Thereof. U.S. Patent 6,066,635, 2000. [Google Scholar]
- Wulff, J.E.; Siegrist, R.; Myers, A.G. The Natural Product Avrainvillamide Binds to the Oncoprotein Nucleophosmin. J. Am. Chem. Soc. 2007, 129, 14444–14451. [Google Scholar] [CrossRef] [Green Version]
- Mukherjee, H.; Chan, K.-P.; Andresen, V.; Hanley, M.L.; Gjertsen, B.T.; Myers, A.G. Interactions of the Natural Product (+)-Avrainvillamide with Nucleophosmin and Exportin-1 Mediate the Cellular Localization of Nucleophosmin and its AML-Associated Mutants. ACS Chem. Biol. 2015, 10, 855–863. [Google Scholar] [CrossRef]
- Andresen, V.; Erikstein, B.S.; Mukherjee, H.; Sulen, A.; Popa, M.; Sørnes, S.; Reikvam, H.; Chan, K.-P.; Hovland, R.; McCormack, E.; et al. Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia. Cell Death Dis 2016, 7, e2497. [Google Scholar] [CrossRef] [Green Version]
- Li, F.; Yi, S.; Wen, L.; He, J.; Yang, L.; Zhao, J.; Zhang, B.; Cui, G.; Chen, Y. Oridonin induces NPM mutant protein translocation and apoptosis in NPM1c+ acute myeloid leukemia cells in vitro. Acta Pharm. Sin. 2014, 35, 806–813. [Google Scholar] [CrossRef]
- Sarwar, M.S.; Xia, Y.-X.; Liang, Z.-M.; Tsang, S.W.; Zhang, H.-J. Mechanistic Pathways and Molecular Targets of Plant-Derived Anticancer ent-Kaurane Diterpenes. Biomolecules 2020, 10, 144. [Google Scholar] [CrossRef] [Green Version]
- Wang, Y.; Ma, W.; Zheng, W. Deguelin, a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention. Mol. Clin. Oncol. 2013, 1, 215–219. [Google Scholar] [CrossRef]
- Varughese, R.S.; Lam, W.S.; Marican, A.A.b.H.; Viganeshwari, S.H.; Bhave, A.S.; Syn, N.L.; Wang, J.; Wong, A.L.; Kumar, A.P.; Lobie, P.E.; et al. Biopharmacological considerations for accelerating drug development of deguelin, a rotenoid with potent chemotherapeutic and chemopreventive potential. Cancer 2019, 125, 1789–1798. [Google Scholar] [CrossRef] [PubMed]
- Yi, S.; Wen, L.; He, J.; Wang, Y.; Zhao, F.; Zhao, J.; Zhao, Z.; Cui, G.; Chen, Y. Deguelin, a selective silencer of the NPM1 mutant, potentiates apoptosis and induces differentiation in AML cells carrying the NPM1 mutation. Ann. Hematol 2015, 94, 201–210. [Google Scholar] [CrossRef] [PubMed]
- Zhang, X.; Zhao, Z.; Yi, S.; Wen, L.; He, J.; Hu, J.; Ruan, J.; Fang, J.; Chen, Y. Deguelin induced differentiation of mutated NPM1 acute myeloid leukemia in vivo and in vitro. Anti-Cancer Drugs 2017, 28, 723–738. [Google Scholar] [CrossRef] [PubMed]
- Chi, H.T.; Ly, B.T.K.; Vu, H.A.; Sato, Y.; Dung, P.C.; Xinh, P.T. Down-regulated expression of NPM1 in IMS-M2 cell line by (−)-epigallocatechin-3-gallate. Asian Pac. J. Trop. Biomed. 2014, 4, 570–574. [Google Scholar] [CrossRef] [Green Version]
- Sharifi-Rad, M.; Pezzani, R.; Redaelli, M.; Zorzan, M.; Imran, M.; Ahmed Khalil, A.; Salehi, B.; Sharopov, F.; Cho, W.C.; Sharifi-Rad, J. Preclinical Activities of Epigallocatechin Gallate in Signaling Pathways in Cancer. Molecules 2020, 25, 467. [Google Scholar] [CrossRef] [Green Version]
- Qi, W.; Shakalya, K.; Stejskal, A.; Goldman, A.; Beeck, S.; Cooke, L.; Mahadevan, D. NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells. Oncogene 2008, 27, 4210–4220. [Google Scholar] [CrossRef] [Green Version]
- Zhang, J.; Zhao, H.L.; He, J.F.; Li, H.Y. Inhibitory Effect of NSC348884, a Small Molecular Inhibitor of Nucleophosmin, on the Growth of Hepatocellular Carcinoma Cell Line hepG2. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2012, 34, 58–61. [Google Scholar]
- Maiguel, D.A.; Jones, L.; Chakravarty, D.; Yang, C.; Carrier, F. Nucleophosmin Sets a Threshold for p53 Response to UV Radiation. Mol. Cell Biol. 2004, 24, 3703–3711. [Google Scholar] [CrossRef] [Green Version]
- Lindström, M.S.; Zhang, Y. B23 and ARF: Friends or Foes? Cell Biochem. Biophys. 2006, 46, 79–90. [Google Scholar] [CrossRef]
- Balusu, R.; Fiskus, W.; Rao, R.; Chong, D.G.; Nalluri, S.; Mudunuru, U.; Ma, H.; Chen, L.; Venkannagari, S.; Ha, K.; et al. Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1. Blood 2011, 118, 3096–3106. [Google Scholar] [CrossRef]
- Šašinková, M.; Heřman, P.; Holoubek, A.; Strachotová, D.; Otevřelová, P.; Grebeňová, D.; Kuželová, K.; Brodská, B. NSC348884 cytotoxicity is not mediated by inhibition of nucleophosmin oligomerization. bioRxiv 2020. [Google Scholar] [CrossRef]
- Jian, Y.; Gao, Z.; Sun, J.; Shen, Q.; Feng, F.; Jing, Y.; Yang, C. RNA aptamers interfering with nucleophosmin oligomerization induce apoptosis of cancer cells. Oncogene 2009, 28, 4201–4211. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nimjee, S.M.; White, R.R.; Becker, R.C.; Sullenger, B.A. Aptamers as Therapeutics. Annu. Rev. Pharm. Toxicol. 2017, 57, 61–79. [Google Scholar] [CrossRef] [PubMed]
- Sekhar, K.R.; Reddy, Y.T.; Reddy, P.N.; Crooks, P.A.; Venkateswaran, A.; McDonald, W.H.; Geng, L.; Sasi, S.; Van Der Waal, R.P.; Roti, J.L.R.; et al. The Novel Chemical Entity YTR107 Inhibits Recruitment of Nucleophosmin to Sites of DNA Damage, Suppressing Repair of DNA Double-Strand Breaks and Enhancing Radiosensitization. Clin. Cancer Res. 2011, 17, 6490–6499. [Google Scholar] [CrossRef] [Green Version]
- Koike, A.; Nishikawa, H.; Wu, W.; Okada, Y.; Venkitaraman, A.R.; Ohta, T. Recruitment of Phosphorylated NPM1 to Sites of DNA Damage through RNF8-Dependent Ubiquitin Conjugates. Cancer Res. 2010, 70, 6746–6756. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Penthala, N.R.; Ketkar, A.; Sekhar, K.R.; Freeman, M.L.; Eoff, R.L.; Balusu, R.; Crooks, P.A. 1-Benzyl-2-methyl-3-indolylmethylene barbituric acid derivatives: Anti-cancer agents that target nucleophosmin 1 (NPM1). Bioorganic Med. Chem. 2015, 23, 7226–7233. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Perea, S.E.; Reyes, O.; Baladron, I.; Perera, Y.; Farina, H.; Gil, J.; Rodriguez, A.; Bacardi, D.; Marcelo, J.L.; Cosme, K.; et al. CIGB-300, a Novel Proapoptotic Peptide That Impairs the CK2 Phosphorylation and Exhibits Anticancer Properties Both in Vitro and in Vivo. Mol. Cell Biochem. 2008, 316, 163–167. [Google Scholar] [CrossRef]
- Martins, L.R.; Perera, Y.; Lúcio, P.; Silva, M.G.; Perea, S.E.; Barata, J.T. Targeting Chronic Lymphocytic Leukemia Using CIGB-300, a Clinical-Stage CK2-specific Cell-Permeable Peptide Inhibitor. Oncotarget 2014, 5, 258–263. [Google Scholar] [CrossRef] [Green Version]
- Benavent Acero, F.; Capobianco, C.S.; Garona, J.; Cirigliano, S.M.; Perer, Y.; Urtreger, A.J.; Perea, S.E.; Alonso, D.F.; Farina, H.G. CIGB-300, an anti-CK2 Peptide, Inhibits Angiogenesis, Tumor Cell Invasion and Metastasis in Lung Cancer Models. Lung Cancer 2017, 107, 14–21. [Google Scholar] [CrossRef] [Green Version]
- Sarduy, M.R.; García, I.; Coca, M.A.; Perera, A.; Torres, L.A.; Valenzuela, C.M.; Baladrón, I.; Solares, M.; Reyes, V.; Hernández, I.; et al. Optimizing CIGB-300 Intralesional Delivery in Locally Advanced Cervical Cancer. Br. J. Cancer 2015, 112, 1636–1643. [Google Scholar] [CrossRef] [Green Version]
- Louvet, E.; Junéra, H.R.; Berthuy, I.; Hernandez-Verdun, D. Compartmentation of the Nucleolar Processing Proteins in the Granular Component Is a CK2-driven Process. Mol Bio Cell 2006, 17, 2537–2546. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Okuwaki, M. The Structure and Functions of NPM1/Nucleophsmin/B23, a Multifunctional Nucleolar Acidic Protein. J. Biochem. 2008, 143, 441–448. [Google Scholar] [CrossRef] [PubMed]
- Shandilya, J.; Senapati, P.; Dhanasekaran, K.; Bangalore, S.S.; Kumar, M.; Hari Kishore, A.; Bhat, A.; Kodaganur, G.S.; Kundu, T.K. Phosphorylation of multifunctional nucleolar protein nucleophosmin (NPM1) by aurora kinase B is critical for mitotic progression. FEBS Lett. 2014, 588, 2198–2205. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rapozzi, V.; Zorzet, S.; Zacchigna, M.; Della Pietra, E.; Cogoi, S.; Xodo, L.E. Anticancer activity of cationic porphyrins in melanoma tumour-bearing mice and mechanistic in vitro studies. Mol. Cancer 2014, 13, 75. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, Y.-Q.; Zhang, Y.-H.; Xie, J.; Li, M.-N.; Liu, Z.-R.; Shen, J.-Y.; Shi, S.-S.; Lan, X.-Y.; Wang, S.; Cheng, N.-L. TMPyP4-regulated cell proliferation and apoptosis through the Wnt/β-catenin signaling pathway in SW480 cells. J. Recept. Signal. Transduct. 2016, 36, 167–172. [Google Scholar] [CrossRef] [PubMed]
- Zidanloo, S.G.; Hosseinzadeh Colagar, A.; Ayatollahi, H.; Raoof, J.-B. Downregulation of the WT1 gene expression via TMPyP4 stabilization of promoter G-quadruplexes in leukemia cells. Tumor Biol. 2016, 37, 9967–9977. [Google Scholar] [CrossRef] [PubMed]
- Cheng, M.-J.; Cao, Y.-G. TMPYP4 exerted antitumor effects in human cervical cancer cells through activation of p38 mitogen-activated protein kinase. Biol. Res. 2017, 50, 24. [Google Scholar] [CrossRef] [Green Version]
- De Cola, A.; Pietrangelo, L.; Forlì, F.; Barcaroli, D.; Budani, M.C.; Graziano, V.; Protasi, F.; Di Ilio, C.; De Laurenzi, V.; Federici, L. AML cells carrying NPM1 mutation are resistant to nucleophosmin displacement from nucleoli caused by the G-quadruplex ligand TmPyP4. Cell Death Dis. 2014, 5, e1427. [Google Scholar] [CrossRef] [Green Version]
- Emmott, E.; Hiscox, J.A. Nucleolar targeting: The hub of the matter. EMBO Rep. 2009, 10, 231–238. [Google Scholar] [CrossRef] [Green Version]
- Destouches, D.; Page, N.; Hamma-Kourbali, Y.; Machi, V.; Chaloin, O.; Frechault, S.; Birmpas, C.; Katsoris, P.; Beyrath, J.; Albanese, P.; et al. A Simple Approach to Cancer Therapy Afforded by Multivalent Pseudopeptides That Target Cell-Surface Nucleoproteins. Cancer Res. 2011, 71, 3296–3305. [Google Scholar] [CrossRef] [Green Version]
- Gilles, M.-E.; Maione, F.; Cossutta, M.; Carpentier, G.; Caruana, L.; Di Maria, S.; Houppe, C.; Destouches, D.; Shchors, K.; Prochasson, C.; et al. Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature. Cancer Res. 2016, 76, 7181–7193. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Diamantopoulou, Z.; Gilles, M.-E.; Sader, M.; Cossutta, M.; Vallée, B.; Houppe, C.; Habert, D.; Brissault, B.; Leroy, E.; Maione, F.; et al. Multivalent cationic pseudopeptide polyplexes as a tool for cancer therapy. Oncotarget 2017, 8, 90108–90122. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- De Cola, A.; Franceschini, M.; Di Matteo, A.; Colotti, G.; Celani, R.; Clemente, E.; Ippoliti, R.; Cimini, A.M.; Dhez, A.C.; Vallée, B.; et al. N6L pseudopeptide interferes with nucleophosmin protein–protein interactions and sensitizes leukemic cells to chemotherapy. Cancer Lett. 2018, 412, 272–282. [Google Scholar] [CrossRef] [PubMed]
- Poletto, M.; Malfatti, M.C.; Dorjsuren, D.; Scognamiglio, P.L.; Marasco, D.; Vascotto, C.; Jadhav, A.; Maloney, D.J.; Wilson, D.M.; Simeonov, A.; et al. Inhibitors of the apurinic/apyrimidinic endonuclease 1 (APE1)/nucleophosmin (NPM1) interaction that display anti-tumor properties. Mol. Carcinog. 2016, 55, 688–704. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Malfatti, M.C.; Gerratana, L.; Dalla, E.; Isola, M.; Damante, G.; Di Loreto, C.; Puglisi, F.; Tell, G. APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC. J. Exp. Clin. Cancer Res. 2019, 38, 309. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jans, D.A.; Martin, A.J.; Wagstaff, K.M. Inhibitors of nuclear transport. Curr. Opin. Cell Biol. 2019, 58, 50–60. [Google Scholar] [CrossRef] [PubMed]
- Das, A.; Wei, G.; Parikh, K.; Liu, D. Selective inhibitors of nuclear export (SINE) in hematological malignancies. Exp. Hematol. Oncol. 2015, 4, 7. [Google Scholar] [CrossRef] [Green Version]
- Ranganathan, P.; Yu, X.; Na, C.; Santhanam, R.; Shacham, S.; Kauffman, M.; Walker, A.; Klisovic, R.; Blum, W.; Caligiuri, M.; et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood 2012, 120, 1765–1773. [Google Scholar] [CrossRef]
- Ranganathan, P.; Kashyap, T.; Yu, X.; Meng, X.; Lai, T.-H.; McNeil, B.; Bhatnagar, B.; Shacham, S.; Kauffman, M.; Dorrance, A.M.; et al. XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase II to the Nucleus. Clin. Cancer Res. 2016, 22, 6142–6152. [Google Scholar] [CrossRef] [Green Version]
- Brunetti, L.; Gundry, M.C.; Sorcini, D.; Guzman, A.G.; Huang, Y.-H.; Ramabadran, R.; Gionfriddo, I.; Mezzasoma, F.; Milano, F.; Nabet, B.; et al. Mutant NPM1 Maintains the Leukemic State through HOX Expression. Cancer Cell 2018, 34, 499–512.e9. [Google Scholar] [CrossRef] [Green Version]
- Alexander, T.B.; Lacayo, N.J.; Choi, J.K.; Ribeiro, R.C.; Pui, C.-H.; Rubnitz, J.E. Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia. J. Clin. Oncol. 2016, 34, 4094–4101. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, A.Y.; Weiner, H.; Green, M.; Chang, H.; Fulton, N.; Larson, R.A.; Odenike, O.; Artz, A.S.; Bishop, M.R.; Godley, L.A.; et al. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J. Hematol. Oncol. 2018, 11, 4. [Google Scholar] [CrossRef] [Green Version]
- Sweet, K.; Komrokji, R.; Padron, E.; Cubitt, C.L.; Turner, J.G.; Zhou, J.; List, A.F.; Sallman, D.A.; Dawson, J.L.; Sullivan, D.M.; et al. Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia. Clin. Cancer Res. 2020, 26, 54–60. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Etchin, J.; Berezovskaya, A.; Conway, A.S.; Galinsky, I.A.; Stone, R.M.; Baloglu, E.; Senapedis, W.; Landesman, Y.; Kauffman, M.; Shacham, S.; et al. KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells. Leukemia 2017, 31, 143–150. [Google Scholar] [CrossRef] [PubMed]
- Hing, Z.A.; Fung, H.Y.J.; Ranganathan, P.; Mitchell, S.; El-Gamal, D.; Woyach, J.A.; Williams, K.; Goettl, V.M.; Smith, J.; Yu, X.; et al. Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies. Leukemia 2016, 30, 2364–2372. [Google Scholar] [CrossRef] [PubMed] [Green Version]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Cela, I.; Di Matteo, A.; Federici, L. Nucleophosmin in Its Interaction with Ligands. Int. J. Mol. Sci. 2020, 21, 4885. https://doi.org/10.3390/ijms21144885
Cela I, Di Matteo A, Federici L. Nucleophosmin in Its Interaction with Ligands. International Journal of Molecular Sciences. 2020; 21(14):4885. https://doi.org/10.3390/ijms21144885
Chicago/Turabian StyleCela, Ilaria, Adele Di Matteo, and Luca Federici. 2020. "Nucleophosmin in Its Interaction with Ligands" International Journal of Molecular Sciences 21, no. 14: 4885. https://doi.org/10.3390/ijms21144885